OXB Secures Plowshare Therapies as Client for AAV Gene Therapy Manufacturing
Event summary
- OXB signed a deal with Plowshare Therapies to provide process development and AAV GMP manufacturing services.
- The programme will be supported from OXB’s FDA-approved facility in Durham, North Carolina.
- This partnership follows the acquisition of the Durham site by OXB in October 2025.
- Plowshare’s lead programme, PLOW-101, targets maple syrup urine disease (MSUD) and has FDA Orphan Drug designation.
The big picture
The partnership underscores the growing global demand for OXB’s end-to-end viral vector manufacturing capabilities, particularly in the US. It also highlights the strategic importance of OXB’s expanded footprint in the gene therapy sector, as CDMOs increasingly become critical partners for biotech firms developing rare disease treatments.
What we're watching
- Client Diversification
- Whether OXB can sustain momentum in its AAV business through continued client base diversification.
- US Market Growth
- The pace at which OXB’s Durham facility attracts new clients post-acquisition.
- Regulatory Milestones
- How Plowshare Therapies’ progress toward an IND application for PLOW-101 will impact manufacturing demand.
Related topics